表紙
市場調查報告書

胃食道逆流症(GERD)治療藥市場分析:藥物類別(解酸劑,質子幫浦抑制劑,H2受體抑制劑,促進腸胃蠕動劑),各地區、、市場區隔預測

Gastroesophageal Reflux Disease (GERD) Therapeutics Market Analysis By Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro-Kinetic Agents), By Region, And Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 478655
出版日期 內容資訊 英文 80 Pages
商品交期: 2-3個工作天內
價格
Back to Top
胃食道逆流症(GERD)治療藥市場分析:藥物類別(解酸劑,質子幫浦抑制劑,H2受體抑制劑,促進腸胃蠕動劑),各地區、、市場區隔預測 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Analysis By Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro-Kinetic Agents), By Region, And Segment Forecasts, 2014 - 2025
出版日期: 2017年02月20日內容資訊: 英文 80 Pages
簡介

本報告提供全球胃食道逆流症(GERD)治療藥市場相關調查,彙整市場趨勢,藥物類別,各地區趨勢,打入市場的主要企業簡介等資料。

第1章 調查方法及範圍

第2章 摘要整理

第3章 市場變數,趨勢,範圍

  • 市場區隔和範圍
    • 推動市場的要素分析
    • 阻礙市場的要素分析
  • 滲透與成長預測製圖
  • SWOT分析
  • 產業分析:波特五力分析

第4章 藥物類別預測與趨勢分析

  • 藥物類別趨勢分析及市場佔有率
  • 解酸劑
  • H2受體抑制劑
  • 質子幫浦抑制劑
  • 促進腸胃蠕動劑

第5章 各地區預測與趨勢分析

  • 市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第6章 競爭環境

  • 策略架構
  • 市場進入類別
  • 企業簡介
目錄
Product Code: GVR-1-68038-298-3

The global Gastroesophageal Reflux Disease (GERD) therapeutics market is expected to reach USD 4.34 billion by 2025, according to a new study by Grand View Research, Inc. The incidence of acid reflux disorder, also known as heartburn, is rapidly increasing worldwide. Various studies state that almost every person experiences acid reflux once in a lifetime.

The overall market has been experiencing a downturn in terms of revenue in the past several years as the leading drugs for GERD treatment have lost their patent protection, with their market shares now largely consumed by over-the-counter (OTC) and generic medications. Although loss of exclusivity of high-grossing drugs have caused a market fall-off, the demand for acid reducing drugs due to the high prevalence and incidence levels of GERD will prove beneficial to the industry from a commercial standpoint.

GERD is one of the commonly observed recurrent gastrointestinal disorders worldwide. The prevalence of acid reflux and related symptoms has increased across the globe by nearly 50% over the last decade. This disorder not only has major effects on the health and quality of patient lives, but also extends to the healthcare system and economy.

In addition, the occurrence of acid reflux disease increases with age, rendering elderly people more prone to developing a severe form of heartburn. The geriatric subset hence forms a prominent target population for GERD therapeutics.

Further key findings from the study suggest:

Antacids have been identified as the largest drug type segment in terms of revenue share due to their cost-effectiveness and greater consumer accessibility

The rising trend of self-medication in case of heartburn is particularly responsible for the growth in sales of OTC antacids

Proton pump inhibitors accounted for the second largest segment as they are the most commonly prescribed medication for the treatment of acid reflux

Market share of proton pump inhibitors is expected to decline over the forecast period with the loss of patent protection of several leading drugs, such as Nexium and Prilosec, in this segment

North America accounted for the largest regional market in 2016 owing to the presence of a large patient population suffering from heartburn and the availability of OTC generics

On the other hand, Asia Pacific is expected to grow at a fairly high growth rate as compared to other regional markets due to increased adoption of OTC and generic antacids along with rising prevalence of heartburn

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Information Procurement
    • 1.1.1 Purchased database
    • 1.1.2 GVR's internal database
  • 1.2 Research Methodology
  • 1.3 Geographic scope & assumptions
  • 1.4 Region-wise Market Calculation
    • 1.4.1 Region-wise market: Base estimates
    • 1.4.2 Global market: CAGR calculation
  • 1.5 Region-based Segment Share Calculation
  • 1.6 List of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 GERD Therapeutics Market Variables, Trends & Scope

  • 3.1 Market Segmentation&Scope
    • 3.1.1 Market drivers analysis
    • 3.1.2 Market Restraints Analysis
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 GERD therapeutics- SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 GERD Therapeutics Market: Drug Type Estimates & Trend Analysis

  • 4.1 GERD Therapeutics Market: Drug type movement analysis
  • 4.2 Antacids
    • 4.2.1 Antacids market, 2014 - 2025 (USDMillion)
  • 4.3 H2 Receptor Blockers
    • 4.3.1 H2 receptor blockers market, 2014 - 2025 (USDMillion)
  • 4.4 Proton Pump Inhibitors
    • 4.4.1 Proton pump inhibitors market, 2014 - 2025 (USDMillion)
  • 4.5 Pro-kinetic Agents
    • 4.5.1 Pro-kinetic agents market, 2014 - 2025 (USDMillion)

Chapter 5 GERD Therapeutics Market: Regional Estimates & Trend Analysis

  • 5.1 GERD Therapeutics Market Share, by Region, 2015 & 2025
  • 5.2 North America
    • 5.2.1 North America GERD therapeutics market, 2014 - 2025 (USDMillion)
    • 5.2.2 U.S
      • 5.2.2.1 U.S GERD therapeutics market, 2014 - 2025 (USD Million)
    • 5.2.3 Canada
      • 5.2.3.1 Canada GERD therapeutics market, 2014 - 2025 (USDMillion)
  • 5.3 Europe
    • 5.3.1 Europe GERD therapeutics market, 2014 - 2025 (USDMillion)
    • 5.3.2 UK
      • 5.3.2.1 UK GERD therapeutics market, 2014 - 2025 (USDMillion)
    • 5.3.3 Germany
      • 5.3.3.1 Germany GERD therapeutics market, 2014 - 2025 (USDMillion)
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific GERD therapeutics market, 2014 - 2025 (USDMillion)
    • 5.4.2 Japan
      • 5.4.2.1 Japan GERD therapeutics market, 2014 - 2025 (USDMillion)
    • 5.4.3 China
      • 5.4.3.1 China GERD therapeutics market, 2014 - 2025 (USDMillion)
  • 5.5 Latin America
    • 5.5.1 Latin America GERD therapeutics market, 2014 - 2025 (USDMillion)
    • 5.5.2 Brazil
      • 5.5.2.1 Brazil GERD therapeutics market, 2014 - 2025 (USDMillion)
  • 5.6 MEA
    • 5.6.1 MEA GERD therapeutics market, 2014 - 2025 (USDMillion)
    • 5.6.2 South Africa
      • 5.6.2.1 South Africa GERD therapeutics market, 2014 - 2025 (USDMillion)

Chapter 6 Competitive Landscape

  • 6.1 Strategy Framework
  • 6.2 Market Participation Categorization
  • 6.3 Company Profiles
    • 6.3.1 Takeda Pharmaceutical Co., Ltd.
      • 6.3.1.1 Company overview
      • 6.3.1.2 Financial performance
      • 6.3.1.3 Product benchmarking
      • 6.3.1.4 Strategic initiatives
    • 6.3.2 AstraZeneca PLC
      • 6.3.2.1 Company overview
      • 6.3.2.2 Financial performance
      • 6.3.2.3 Product benchmarking
      • 6.3.2.4 Strategic initiatives
    • 6.3.3 Eisai Co., Ltd.
      • 6.3.3.1 Company overview
      • 6.3.3.2 Financial performance
      • 6.3.3.3 Product benchmarking
      • 6.3.3.4 Strategic initiatives
    • 6.3.4 GlaxoSmithKline PLC
      • 6.3.4.1 Company overview
      • 6.3.4.2 Financial performance
      • 6.3.4.3 Product benchmarking
      • 6.3.4.4 Strategic initiatives
    • 6.3.5 Johnson & Johnson Services, Inc.
      • 6.3.5.1 Company overview
      • 6.3.5.2 Financial performance
      • 6.3.5.3 Product benchmarking
      • 6.3.5.4 Strategic initiatives
    • 6.3.6 Daewoong Pharmaceutical Co., Ltd
      • 6.3.6.1 Company overview
      • 6.3.6.2 Financial overview
      • 6.3.6.3 Product benchmarking
      • 6.3.6.4 Strategic initiatives
    • 6.3.7 Ironwood Pharmaceuticals, Inc.
      • 6.3.7.1 Company overview
      • 6.3.7.2 Financial overview
      • 6.3.7.3 Product benchmarking
      • 6.3.7.4 Strategic initiatives
    • 6.3.8 RaQualia Pharma, Inc.
      • 6.3.8.1 Company overview
      • 6.3.8.2 Financial overview
      • 6.3.8.3 Product benchmarking
      • 6.3.8.4 Strategic initiatives
    • 6.3.9 SFJ Pharmaceuticals Group
      • 6.3.9.1 Company overview
      • 6.3.9.2 Financial overview
      • 6.3.9.3 Product benchmarking
      • 6.3.9.4 Strategic initiatives
    • 6.3.10 SRS Pharmaceuticals Pvt. Ltd
      • 6.3.10.1 Company overview
      • 6.3.10.2 Financial overview
      • 6.3.10.3 Product benchmarking
      • 6.3.10.4 Strategic initiatives
    • 6.3.11 Reckitt Benckiser Group PLC
      • 6.3.11.1 Company overview
      • 6.3.11.2 Financial overview
      • 6.3.11.3 Product benchmarking
      • 6.3.11.4 Strategic initiatives
    • 6.3.12 Novartis AG
      • 6.3.12.1 Company overview
      • 6.3.12.2 Financial overview
      • 6.3.12.3 Product benchmarking
      • 6.3.12.4 Strategic initiatives
    • 6.3.13 Pfizer, Inc.
      • 6.3.13.1 Company overview
      • 6.3.13.2 Financial overview
      • 6.3.13.3 Product benchmarking
      • 6.3.13.4 Strategic initiatives
    • 6.3.14 Abbott
      • 6.3.14.1 Company overview
      • 6.3.14.2 Financial overview
      • 6.3.14.3 Product benchmarking
      • 6.3.14.4 Strategic initiatives

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 North America GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 3 U.S. GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 4 Canada GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 5 Europe GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 6 UK GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 7 Germany GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 8 Asia Pacific GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 9 Japan GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 10 China GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 11 Latin America GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 12 Brazil GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 13 MEA GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 14 South Africa GERD therapeutics market, by drug type, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Value chain-based sizing & forecasting
  • FIG. 4 QFD modeling for market share assessment
  • FIG. 5 Market summary, 2015
  • FIG. 6 Market trends & outlook
  • FIG. 7 Market segmentation & scope
  • FIG. 8 Market driver relevance analysis (Current & future impact)
  • FIG. 9 Market restraint relevance analysis (Current & future impact)
  • FIG. 10 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 11 Porter's Five Forces Analysis
  • FIG. 12 Company Market Share Analysis - IVD Quality Control Market, 2015
  • FIG. 13 GERD therapeutics market drug type outlook key takeaways
  • FIG. 14 GERD therapeutics market: Drug type movement analysis
  • FIG. 15 Global antacids market, 2014 - 2025 (USD Million)
  • FIG. 16 Global H2 receptor blockers market, 2014 - 2025 (USD Million)
  • FIG. 17 Global proton pump inhibitors market, 2014 - 2025 (USD Million)
  • FIG. 18 Global pro-kinetic agents market, 2014 - 2025 (USD Million)
  • FIG. 19 Regional market place: Key takeaways
  • FIG. 20 Regional outlook, 2015 & 2025
  • FIG. 21 North America GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 22 U.S. GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 23 Canada GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 24 Europe GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 25 UK GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 26 Germany GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 27 Asia Pacific GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 28 Japan GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 29 China GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 30 Latin America GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 31 Mexico GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 32 Brazil GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 33 MEA GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 34 South Africa GERD therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 35 Strategy framework
  • FIG. 36 Participant categorization
Back to Top